In this large multicenter study of HER2-positive gastric cancer, we observed in patients with disease progression after trastuzumab-containing platinum-based therapy that changing chemotherapy with continuation of trastuzumab was associated with improved clinical outcomes. The gene discussed is ERBB2; the disease is gastric cancer.